Compare NVDA & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVDA | AZN |
|---|---|---|
| Founded | 1993 | 1992 |
| Country | US | |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4T | 285.7B |
| IPO Year | 1998 | N/A |
| Metric | NVDA | AZN |
|---|---|---|
| Price | $187.64 | $208.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 39 | 1 |
| Target Price | ★ $255.82 | N/A |
| AVG Volume (30 Days) | ★ 137.6M | 4.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 0.02% | ★ 1.53% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $130,497,000,000.00 | N/A |
| Revenue This Year | $66.50 | $9.84 |
| Revenue Next Year | $54.53 | $6.16 |
| P/E Ratio | $59.76 | ★ $31.91 |
| Revenue Growth | ★ 114.20 | N/A |
| 52 Week Low | $86.63 | $61.24 |
| 52 Week High | $212.19 | $212.71 |
| Indicator | NVDA | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 87.12 |
| Support Level | $179.18 | $187.06 |
| Resistance Level | $193.61 | $193.97 |
| Average True Range (ATR) | 7.27 | 4.23 |
| MACD | 0.19 | 4.29 |
| Stochastic Oscillator | 59.57 | 96.80 |
Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence to run large language models. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.